Xilio Therapeutics (XLO) Non-Current Deffered Revenue (2024 - 2026)

Xilio Therapeutics (XLO) has 3 years of Non-Current Deffered Revenue data on file, last reported at $16.5 million in Q1 2026.

• For the quarter ending Q1 2026, Non-Current Deffered Revenue fell 57.49% year-over-year to $16.5 million; the trailing twelve-month figure through Mar 2026 stood at $16.5 million (down 57.49% YoY), and the FY2025 full-year result was $20.6 million, up 7.13% from the prior year.
• Non-Current Deffered Revenue declined to $16.5 million in Q1 2026, from $20.6 million in the prior quarter.
• In the past five years, Non-Current Deffered Revenue ranged from a high of $38.7 million in Q1 2025 to a low of $8.4 million in Q3 2024.
• A 3-year average of $20.6 million and a median of $19.3 million in 2024 frame the typical range for Non-Current Deffered Revenue.
• Across the five-year window, Non-Current Deffered Revenue soared 203.58% in 2025 and sank 57.49% in 2026, its largest moves.
• Tracing XLO's Non-Current Deffered Revenue over 3 years: stood at $19.3 million in 2024, then grew by 7.13% to $20.6 million in 2025, then retreated by 20.19% to $16.5 million in 2026.
• Business Quant data shows XLO's Non-Current Deffered Revenue at $16.5 million in Q1 2026, $20.6 million in Q4 2025, and $25.5 million in Q3 2025.